[1] |
WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken .
Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
|
[2] |
LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin.
Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
|
[3] |
ZHAO Lu, LI Fuyong, WEN Binhong, LI Daowei.
Effects of stains on hyperlipidemia and pain relieve of patients with chronic migraine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 671-675.
|
[4] |
CAI Zuhuan, DENG Taomei, WEI Naijie, ZHU Dan, QIAN Fei, WANG Guangji, ZHANG Jingwei.
Silybin ameliorates lipid metabolism disorders in mice with non-alco-holic steatohepatitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 241-248.
|
[5] |
LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong.
Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
|
[6] |
TANG Zizhao, NIE Fangqin, YAN Xin, FU Yangxia, HUANG Jun, WANG Xia, GUO Ren.
Effect of Atglistatin on PA-induced VSMCs proliferation and ATGL expression
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 29-35.
|
[7] |
WANG Xin, LIU Weiying, WU Chen, KAI Jinjun, LIANG Xuejie, CHANG Yingxuan.
Metformin regulates AMPK/SREBP-1 pathway and its clinical application
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1049-1054.
|
[8] |
WANG Kai, SONG Min, SONG Zhijing, LI Jinyi.
Mechanism of vascular endothelial cells ferroptosis in cervical spondylosis of vertebral artery type
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 588-594.
|
[9] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Evinacumab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
|
[10] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Inclisiran
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
|
[11] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
|
[12] |
WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming.
Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
|
[13] |
DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli.
Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
|
[14] |
LI Wenxia, FANG Liuyuan, QIAN Shenxian.
Mechanism of ferroptosis and its research progress in lymphoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 314-321.
|
[15] |
ZHANG Liang, LIAO Yongqun, XIA Qinchuan, ZHOU Shitong, LI Xiaoli.
Ferroptosis regulatory signaling pathway and its research progress in related diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 227-234.
|